Share Price and Basic Stock Data
Last Updated: December 12, 2025, 2:34 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Mangalam Drugs and Organics Ltd operates within the competitive pharmaceutical sector, with a market capitalization of ₹39.2 Cr and a current share price of ₹24.8. Over the last year, the company’s revenue has experienced significant fluctuations, which is evident in the reported sales figures. For instance, the revenue peaked at ₹451 Cr in FY 2022 but subsequently declined to ₹372 Cr in FY 2023 and slightly further to ₹369 Cr in FY 2024. This downward trend raises concerns, especially when juxtaposed against the backdrop of a growing pharmaceutical market in India, which is anticipated to reach ₹4.4 lakh Cr by 2025. While the company has shown resilience by returning to positive sales in recent quarters, with ₹102 Cr reported in March 2024, the variability in quarterly sales—like the dip to ₹63 Cr in December 2022—signals potential challenges in maintaining consistent demand and operational stability.
Profitability and Efficiency Metrics
Profitability metrics for Mangalam Drugs have been troubling. The company reported a negative net profit of ₹9 Cr in FY 2023, which reflects a continuous struggle to control costs amidst fluctuating revenues. Operating profit margins (OPM) have oscillated, with a reported OPM of -8% in the latest figures, indicating that the company is currently grappling with high operational costs relative to its sales. The operating profit (OP) has seen a slight recovery, reaching ₹12 Cr in March 2024, yet the overall profitability remains a concern as reflected by a return on equity (ROE) of just 4.71%. Comparatively, many peers in the pharmaceutical sector boast ROEs in the double digits, highlighting a potential area for improvement. Furthermore, the interest coverage ratio stands at a comfortable 2.43x, suggesting that while interest obligations are manageable, the overall profit generation must improve to enhance investor confidence.
Balance Sheet Strength and Financial Ratios
Mangalam Drugs’ balance sheet presents a mixed picture. With total borrowings of ₹95 Cr and reserves of ₹112 Cr, the company exhibits a debt-to-equity ratio of 0.54, which is relatively modest and reflects a conservative approach to leveraging. However, the cash conversion cycle (CCC) has extended to 148 days, suggesting inefficiencies in managing working capital—an area that could be optimized for better cash flow management. The book value per share has risen to ₹94.12, indicating a potential buffer for shareholders, yet the price-to-book value ratio of 0.78x highlights that the stock is trading below its book value, a sign that the market remains skeptical about the company’s future earnings potential. Such financial ratios indicate that while the company is maintaining a reasonable level of financial health, it faces challenges in translating its assets into effective operational performance.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Mangalam Drugs reveals a significant commitment from promoters, holding approximately 50.30% of shares. This alignment can often instill confidence among retail investors, as it suggests that those with the most to lose are invested in the company’s success. However, foreign institutional investors (FIIs) hold a mere 0.11%, which may indicate a lack of interest or confidence from larger institutional players. The total number of shareholders has grown to 19,881, reflecting a slowly increasing public interest in the stock. Despite the uptick in shareholder numbers, the overall lack of institutional backing is a concern; it may signal to potential investors that the broader market sentiment towards Mangalam Drugs remains cautious. Maintaining investor confidence will be crucial as the company navigates its operational challenges.
Outlook, Risks, and Final Insight
Looking ahead, Mangalam Drugs faces a dual-edged sword of opportunities and risks. While the pharmaceutical sector is poised for growth, the company’s inconsistent revenue streams and profitability metrics present significant risks. The variability in sales and the negative net profits recorded in recent periods could deter potential investors. Additionally, the extended cash conversion cycle poses a risk to liquidity, which is critical for operational flexibility. On the flip side, if the company can streamline its operations and improve its cost structure, there could be potential for recovery. Investors should watch how Mangalam Drugs tackles these operational inefficiencies while also keeping an eye on the broader market trends. The ability to adapt to changing market conditions and improve profitability will be key determinants of its future success, making this stock a possible high-risk, high-reward scenario for investors willing to engage in the pharmaceutical sector’s dynamic landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Mangalam Drugs and Organics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 141 Cr. | 112 | 239/84.3 | 31.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,246 Cr. | 390 | 479/192 | 87.9 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.0 Cr. | 44.5 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 43.8 Cr. | 29.9 | 31.0/17.0 | 104 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,461.38 Cr | 1,157.79 | 51.81 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 109 | 108 | 63 | 91 | 87 | 82 | 97 | 102 | 77 | 80 | 89 | 73 | 57 |
| Expenses | 99 | 100 | 57 | 91 | 91 | 79 | 90 | 91 | 68 | 71 | 80 | 63 | 62 |
| Operating Profit | 10 | 8 | 6 | 0 | -3 | 2 | 7 | 12 | 8 | 9 | 9 | 10 | -5 |
| OPM % | 9% | 8% | 10% | 0% | -4% | 3% | 7% | 11% | 11% | 11% | 10% | 14% | -8% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 4 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 3 | 4 | 4 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 5 | 4 |
| Profit before tax | 4 | 3 | 1 | -6 | -10 | -5 | 0 | 4 | 1 | 1 | 1 | 2 | -13 |
| Tax % | 29% | 29% | 16% | -22% | -7% | -25% | -920% | 10% | -356% | -125% | 5% | 91% | 6% |
| Net Profit | 3 | 2 | 0 | -4 | -10 | -4 | 0 | 4 | 3 | 3 | 1 | 0 | -14 |
| EPS in Rs | 1.90 | 1.41 | 0.27 | -2.77 | -6.03 | -2.25 | 0.32 | 2.24 | 1.69 | 1.70 | 0.88 | 0.09 | -8.67 |
Last Updated: August 20, 2025, 7:15 am
Below is a detailed analysis of the quarterly data for Mangalam Drugs and Organics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 57.00 Cr.. The value appears to be declining and may need further review. It has decreased from 73.00 Cr. (Mar 2025) to 57.00 Cr., marking a decrease of 16.00 Cr..
- For Expenses, as of Jun 2025, the value is 62.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 63.00 Cr. (Mar 2025) to 62.00 Cr., marking a decrease of 1.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 10.00 Cr. (Mar 2025) to -5.00 Cr., marking a decrease of 15.00 Cr..
- For OPM %, as of Jun 2025, the value is -8.00%. The value appears to be declining and may need further review. It has decreased from 14.00% (Mar 2025) to -8.00%, marking a decrease of 22.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00 Cr..
- For Depreciation, as of Jun 2025, the value is 4.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.00 Cr. (Mar 2025) to 4.00 Cr., marking a decrease of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to -13.00 Cr., marking a decrease of 15.00 Cr..
- For Tax %, as of Jun 2025, the value is 6.00%. The value appears to be improving (decreasing) as expected. It has decreased from 91.00% (Mar 2025) to 6.00%, marking a decrease of 85.00%.
- For Net Profit, as of Jun 2025, the value is -14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.00 Cr. (Mar 2025) to -14.00 Cr., marking a decrease of 14.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -8.67. The value appears to be declining and may need further review. It has decreased from 0.09 (Mar 2025) to -8.67, marking a decrease of 8.76.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:53 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 123 | 221 | 295 | 299 | 269 | 228 | 282 | 380 | 451 | 372 | 369 | 318 | 299 |
| Expenses | 113 | 200 | 257 | 252 | 222 | 218 | 259 | 327 | 402 | 347 | 351 | 282 | 276 |
| Operating Profit | 10 | 20 | 38 | 47 | 47 | 10 | 24 | 53 | 49 | 26 | 17 | 36 | 23 |
| OPM % | 8% | 9% | 13% | 16% | 17% | 4% | 8% | 14% | 11% | 7% | 5% | 11% | 8% |
| Other Income | 0 | 0 | 0 | -0 | 1 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | 0 |
| Interest | 10 | 10 | 9 | 10 | 12 | 9 | 10 | 9 | 11 | 13 | 14 | 15 | 15 |
| Depreciation | 4 | 4 | 4 | 5 | 7 | 7 | 8 | 9 | 10 | 11 | 15 | 16 | 17 |
| Profit before tax | -4 | 6 | 24 | 31 | 29 | -6 | 6 | 40 | 28 | 2 | -11 | 5 | -9 |
| Tax % | -22% | -2% | 33% | 29% | 32% | 40% | -32% | 29% | 29% | 43% | -18% | -39% | |
| Net Profit | -3 | 6 | 16 | 22 | 20 | -8 | 8 | 28 | 20 | 1 | -9 | 7 | -9 |
| EPS in Rs | -2.31 | 4.66 | 11.15 | 14.08 | 12.57 | -5.07 | 5.21 | 17.67 | 12.42 | 0.80 | -5.72 | 4.37 | -6.00 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 4% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 300.00% | 166.67% | 37.50% | -9.09% | -140.00% | 200.00% | 250.00% | -28.57% | -95.00% | -1000.00% | 177.78% |
| Change in YoY Net Profit Growth (%) | 0.00% | -133.33% | -129.17% | -46.59% | -130.91% | 340.00% | 50.00% | -278.57% | -66.43% | -905.00% | 1177.78% |
Mangalam Drugs and Organics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
No data available for the compounded sales growth chart.
Balance Sheet
Last Updated: December 4, 2025, 1:37 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 13 | 13 | 14 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | 10 | 16 | 47 | 70 | 88 | 80 | 88 | 115 | 135 | 136 | 127 | 133 | 112 |
| Borrowings | 77 | 78 | 60 | 66 | 69 | 65 | 52 | 70 | 88 | 89 | 107 | 96 | 95 |
| Other Liabilities | 25 | 63 | 38 | 38 | 54 | 50 | 75 | 64 | 90 | 117 | 108 | 114 | 87 |
| Total Liabilities | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 | 310 |
| Fixed Assets | 53 | 53 | 54 | 93 | 102 | 103 | 101 | 118 | 135 | 142 | 147 | 156 | 152 |
| CWIP | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 6 | 6 | 9 | 8 | 3 | 4 |
| Investments | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 72 | 117 | 100 | 95 | 125 | 107 | 128 | 140 | 188 | 206 | 202 | 201 | 155 |
| Total Assets | 125 | 170 | 160 | 190 | 227 | 211 | 231 | 264 | 328 | 358 | 357 | 359 | 310 |
Below is a detailed analysis of the balance sheet data for Mangalam Drugs and Organics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 16.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 16.00 Cr..
- For Reserves, as of Sep 2025, the value is 112.00 Cr.. The value appears to be declining and may need further review. It has decreased from 133.00 Cr. (Mar 2025) to 112.00 Cr., marking a decrease of 21.00 Cr..
- For Borrowings, as of Sep 2025, the value is 95.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 96.00 Cr. (Mar 2025) to 95.00 Cr., marking a decrease of 1.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 87.00 Cr.. The value appears to be improving (decreasing). It has decreased from 114.00 Cr. (Mar 2025) to 87.00 Cr., marking a decrease of 27.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 310.00 Cr.. The value appears to be improving (decreasing). It has decreased from 359.00 Cr. (Mar 2025) to 310.00 Cr., marking a decrease of 49.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 152.00 Cr.. The value appears to be declining and may need further review. It has decreased from 156.00 Cr. (Mar 2025) to 152.00 Cr., marking a decrease of 4.00 Cr..
- For CWIP, as of Sep 2025, the value is 4.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 155.00 Cr.. The value appears to be declining and may need further review. It has decreased from 201.00 Cr. (Mar 2025) to 155.00 Cr., marking a decrease of 46.00 Cr..
- For Total Assets, as of Sep 2025, the value is 310.00 Cr.. The value appears to be declining and may need further review. It has decreased from 359.00 Cr. (Mar 2025) to 310.00 Cr., marking a decrease of 49.00 Cr..
Notably, the Reserves (112.00 Cr.) exceed the Borrowings (95.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -67.00 | -58.00 | -22.00 | -19.00 | -22.00 | -55.00 | -28.00 | -17.00 | -39.00 | -63.00 | -90.00 | -60.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88 | 73 | 37 | 45 | 61 | 28 | 52 | 52 | 38 | 46 | 28 | 45 |
| Inventory Days | 170 | 134 | 85 | 69 | 132 | 175 | 121 | 85 | 139 | 200 | 185 | 303 |
| Days Payable | 97 | 128 | 37 | 38 | 82 | 77 | 106 | 63 | 65 | 139 | 124 | 199 |
| Cash Conversion Cycle | 161 | 79 | 85 | 75 | 111 | 126 | 67 | 74 | 112 | 107 | 88 | 148 |
| Working Capital Days | 29 | 26 | 32 | 19 | 31 | 21 | 10 | 23 | 43 | 38 | 18 | 13 |
| ROCE % | 6% | 16% | 29% | 31% | 25% | 2% | 11% | 27% | 18% | 6% | 1% | 8% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 4.25 | -5.73 |
| Diluted EPS (Rs.) | 4.25 | -5.73 |
| Cash EPS (Rs.) | 14.74 | 3.52 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 94.12 | 85.79 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 94.12 | 85.79 |
| Revenue From Operations / Share (Rs.) | 201.05 | 232.87 |
| PBDIT / Share (Rs.) | 22.95 | 11.05 |
| PBIT / Share (Rs.) | 12.46 | 1.80 |
| PBT / Share (Rs.) | 3.02 | -7.00 |
| Net Profit / Share (Rs.) | 4.25 | -5.73 |
| NP After MI And SOA / Share (Rs.) | 4.25 | -5.73 |
| PBDIT Margin (%) | 11.41 | 4.74 |
| PBIT Margin (%) | 6.19 | 0.77 |
| PBT Margin (%) | 1.50 | -3.00 |
| Net Profit Margin (%) | 2.11 | -2.46 |
| NP After MI And SOA Margin (%) | 2.11 | -2.46 |
| Return on Networth / Equity (%) | 4.51 | -6.68 |
| Return on Capital Employeed (%) | 11.27 | 1.67 |
| Return On Assets (%) | 1.83 | -2.71 |
| Long Term Debt / Equity (X) | 0.06 | 0.09 |
| Total Debt / Equity (X) | 0.54 | 0.64 |
| Asset Turnover Ratio (%) | 0.90 | 0.00 |
| Current Ratio (X) | 1.04 | 1.07 |
| Quick Ratio (X) | 0.31 | 0.31 |
| Inventory Turnover Ratio (X) | 1.30 | 0.00 |
| Interest Coverage Ratio (X) | 2.43 | 1.26 |
| Interest Coverage Ratio (Post Tax) (X) | 1.45 | 0.34 |
| Enterprise Value (Cr.) | 196.06 | 233.41 |
| EV / Net Operating Revenue (X) | 0.61 | 0.63 |
| EV / EBITDA (X) | 5.40 | 13.34 |
| MarketCap / Net Operating Revenue (X) | 0.36 | 0.39 |
| Price / BV (X) | 0.78 | 1.08 |
| Price / Net Operating Revenue (X) | 0.36 | 0.39 |
| EarningsYield | 0.05 | -0.06 |
After reviewing the key financial ratios for Mangalam Drugs and Organics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 4.25. This value is below the healthy minimum of 5. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For Diluted EPS (Rs.), as of Mar 25, the value is 4.25. This value is below the healthy minimum of 5. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For Cash EPS (Rs.), as of Mar 25, the value is 14.74. This value is within the healthy range. It has increased from 3.52 (Mar 24) to 14.74, marking an increase of 11.22.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 94.12. It has increased from 85.79 (Mar 24) to 94.12, marking an increase of 8.33.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 94.12. It has increased from 85.79 (Mar 24) to 94.12, marking an increase of 8.33.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 201.05. It has decreased from 232.87 (Mar 24) to 201.05, marking a decrease of 31.82.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 22.95. This value is within the healthy range. It has increased from 11.05 (Mar 24) to 22.95, marking an increase of 11.90.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.46. This value is within the healthy range. It has increased from 1.80 (Mar 24) to 12.46, marking an increase of 10.66.
- For PBT / Share (Rs.), as of Mar 25, the value is 3.02. This value is within the healthy range. It has increased from -7.00 (Mar 24) to 3.02, marking an increase of 10.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 4.25. This value is within the healthy range. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 4.25. This value is within the healthy range. It has increased from -5.73 (Mar 24) to 4.25, marking an increase of 9.98.
- For PBDIT Margin (%), as of Mar 25, the value is 11.41. This value is within the healthy range. It has increased from 4.74 (Mar 24) to 11.41, marking an increase of 6.67.
- For PBIT Margin (%), as of Mar 25, the value is 6.19. This value is below the healthy minimum of 10. It has increased from 0.77 (Mar 24) to 6.19, marking an increase of 5.42.
- For PBT Margin (%), as of Mar 25, the value is 1.50. This value is below the healthy minimum of 10. It has increased from -3.00 (Mar 24) to 1.50, marking an increase of 4.50.
- For Net Profit Margin (%), as of Mar 25, the value is 2.11. This value is below the healthy minimum of 5. It has increased from -2.46 (Mar 24) to 2.11, marking an increase of 4.57.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 2.11. This value is below the healthy minimum of 8. It has increased from -2.46 (Mar 24) to 2.11, marking an increase of 4.57.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.51. This value is below the healthy minimum of 15. It has increased from -6.68 (Mar 24) to 4.51, marking an increase of 11.19.
- For Return on Capital Employeed (%), as of Mar 25, the value is 11.27. This value is within the healthy range. It has increased from 1.67 (Mar 24) to 11.27, marking an increase of 9.60.
- For Return On Assets (%), as of Mar 25, the value is 1.83. This value is below the healthy minimum of 5. It has increased from -2.71 (Mar 24) to 1.83, marking an increase of 4.54.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.06. This value is below the healthy minimum of 0.2. It has decreased from 0.09 (Mar 24) to 0.06, marking a decrease of 0.03.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.54. This value is within the healthy range. It has decreased from 0.64 (Mar 24) to 0.54, marking a decrease of 0.10.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.90. It has increased from 0.00 (Mar 24) to 0.90, marking an increase of 0.90.
- For Current Ratio (X), as of Mar 25, the value is 1.04. This value is below the healthy minimum of 1.5. It has decreased from 1.07 (Mar 24) to 1.04, marking a decrease of 0.03.
- For Quick Ratio (X), as of Mar 25, the value is 0.31. This value is below the healthy minimum of 1. There is no change compared to the previous period (Mar 24) which recorded 0.31.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.30. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 1.30, marking an increase of 1.30.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.43. This value is below the healthy minimum of 3. It has increased from 1.26 (Mar 24) to 2.43, marking an increase of 1.17.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 3. It has increased from 0.34 (Mar 24) to 1.45, marking an increase of 1.11.
- For Enterprise Value (Cr.), as of Mar 25, the value is 196.06. It has decreased from 233.41 (Mar 24) to 196.06, marking a decrease of 37.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.63 (Mar 24) to 0.61, marking a decrease of 0.02.
- For EV / EBITDA (X), as of Mar 25, the value is 5.40. This value is within the healthy range. It has decreased from 13.34 (Mar 24) to 5.40, marking a decrease of 7.94.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.36, marking a decrease of 0.03.
- For Price / BV (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has decreased from 1.08 (Mar 24) to 0.78, marking a decrease of 0.30.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.36. This value is below the healthy minimum of 1. It has decreased from 0.39 (Mar 24) to 0.36, marking a decrease of 0.03.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from -0.06 (Mar 24) to 0.05, marking an increase of 0.11.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Mangalam Drugs and Organics Ltd:
- Net Profit Margin: 2.11%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 11.27% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.51% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.45
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.31
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 51.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.54
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.11%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Rupam Building, 3rd Floor, Mumbai Maharashtra 400001 | contactus@mangalamdrugs.com http://www.mangalamdrugs.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Govardhan Murlidhar Dhoot | Chairman & Managing Director |
| Mr. Brijmohan Murlidhar Dhoot | Whole Time Director |
| Mr. Praveen Saxena | Independent Director |
| Mr. Rakesh Kishinchand Milwani | Non Exe.Non Ind.Director |
| Mr. Rukmesh Prabhukumar Dhandhania | Independent Director |
| Mrs. Nidhi Shantanu Mundada | Independent Director |
FAQ
What is the intrinsic value of Mangalam Drugs and Organics Ltd?
Mangalam Drugs and Organics Ltd's intrinsic value (as of 12 December 2025) is 46.41 which is 84.90% higher the current market price of 25.10, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 39.7 Cr. market cap, FY2025-2026 high/low of 130/23.6, reserves of ₹112 Cr, and liabilities of 310 Cr.
What is the Market Cap of Mangalam Drugs and Organics Ltd?
The Market Cap of Mangalam Drugs and Organics Ltd is 39.7 Cr..
What is the current Stock Price of Mangalam Drugs and Organics Ltd as on 12 December 2025?
The current stock price of Mangalam Drugs and Organics Ltd as on 12 December 2025 is 25.1.
What is the High / Low of Mangalam Drugs and Organics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Mangalam Drugs and Organics Ltd stocks is 130/23.6.
What is the Stock P/E of Mangalam Drugs and Organics Ltd?
The Stock P/E of Mangalam Drugs and Organics Ltd is .
What is the Book Value of Mangalam Drugs and Organics Ltd?
The Book Value of Mangalam Drugs and Organics Ltd is 80.5.
What is the Dividend Yield of Mangalam Drugs and Organics Ltd?
The Dividend Yield of Mangalam Drugs and Organics Ltd is 0.00 %.
What is the ROCE of Mangalam Drugs and Organics Ltd?
The ROCE of Mangalam Drugs and Organics Ltd is 8.03 %.
What is the ROE of Mangalam Drugs and Organics Ltd?
The ROE of Mangalam Drugs and Organics Ltd is 4.71 %.
What is the Face Value of Mangalam Drugs and Organics Ltd?
The Face Value of Mangalam Drugs and Organics Ltd is 10.0.